CareDx, Inc. (CDNA)

NASDAQ: CDNA · Real-Time Price · USD

22.25

-0.87 (-3.76%)

At close: Jun 5, 2026, 4:00 PM EDT

22.07

-0.18 (-0.81%)

After-hours: Jun 5, 2026, 7:29 PM EDT

-3.76% (1D)

Market Cap	1.15B +16.4%
Revenue (ttm)	412.82M +19.2%
Net Income	-8.19M
EPS	-0.16
Shares Out	51.66M
PE Ratio	n/a
Forward PE	27.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	548,319
Open	23.16
Previous Close	23.12
Day's Range	22.03 - 23.51
52-Week Range	10.96 - 24.02
Beta	2.48
Analysts	Buy
Price Target	25.80 (+15.96%)
Earnings Date	Apr 28, 2026

About CDNA

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about dist... [Read more]

Industry Diagnostics & Research

Sector Healthcare

IPO Date Jul 17, 2014

Employees 765

Stock Exchange NASDAQ

Ticker Symbol CDNA

Website https://caredx.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price target is $25.8, which is an increase of 15.96% from the latest price.

Price Target

$25.8

(15.96% upside)

Analyst Consensus: Buy

Stock Forecasts

News

CareDx Proxy statement: Proxy filing

CareDx filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.

1 day ago - Filings

CareDx Transcript: Jefferies Global Healthcare Conference 2026

Strong Q1 performance with 39% revenue growth led to raised guidance for 2024. Pipeline expansion, including the Naveris acquisition and AlloHeme development, positions the company for leadership in precision diagnostics and oncology MRD, with robust digital integration and targeted commercial strategies.

2 days ago - Transcripts

CareDx denied request to Supreme Court to revive Natera award

A writ of certiorari was denied by the U.S. Supreme Court in the case of CareDx (CDNA) v. Natera (NTRA), meaning that the Court has declined to hear the appeal,…

Other symbols: NTRA

4 days ago - TheFly

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinicall...

16 days ago - Business Wire

CareDx announces dismissal of 2021 Qui Tam Suit

CareDx (CDNA) announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York…

25 days ago - TheFly

CareDx Announces Dismissal of 2021 Qui Tam Suit

25 days ago - Business Wire

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinica...

5 weeks ago - Business Wire

CareDx price target raised to $28 from $26 at BTIG

BTIG raised the firm’s price target on CareDx (CDNA) to $28 from $26 and keeps a Buy rating on the shares. The company has announced many positive updates on its…

5 weeks ago - TheFly

CareDx files automatic mixed securities shelf

17:08 EDT CareDx (CDNA) files automatic mixed securities shelf

5 weeks ago - TheFly

CareDx to acquire Naveris for $160M up-front, $100M in revenue milestones

The Transplant Company announced it has entered into a definitive agreement to acquire Naveris. The transaction is an extension of CareDx’s (CDNA) strategy to focus on its U.S. Precision Medicine…

5 weeks ago - TheFly

CareDx raises FY26 revenue view to $447M-$465M from $420M-$444M

Consensus $437.43M. The Company now expects full year 2026 adjusted EBITDA to be in the range of $43 million to $57 million.

5 weeks ago - TheFly

CareDx Earnings Call Transcript: Q1 2026

Q1 revenue grew 39% year-over-year, driven by strong testing and digital solutions growth. The company divested its lab products business and acquired Navoris, expanding into viral-mediated cancer MRD with a differentiated, Medicare-covered platform. 2026 guidance was raised, with no Navoris contribution included.

5 weeks ago - Transcripts

CareDx Earnings release: Q1 2026

CareDx released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.

5 weeks ago - Filings

CareDx Quarterly report: Q1 2026

CareDx has published its Q1 2026 quarterly earnings report on April 28, 2026.

5 weeks ago - Filings

CareDx Slides: Q1 2026

CareDx has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.

5 weeks ago - Filings

CareDx reports Q1 EPS 34c, consensus 13c

Reports Q1 revenue $118M, consensus $104.45M. “Our team delivered another quarter of record growth, driven by continued momentum in our Precision Medicine Testing Services and Patient and Digital Solu...

5 weeks ago - TheFly